---
layout: post
title: "亚宝药业：药品甲钴胺片通过仿制药一致性评价"
date: 2021-12-22 15:44:51 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600351" data-code="600351|1|1" data-code2="600351|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600351&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600351_0" data-code="K 600351|1|1" data-code2="K 600351|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>亚宝药业(600351)12月22日晚间公告，公司药品甲钴胺片通过仿制药一致性评价。甲钴胺片主要用于治疗周围神经病。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202112222222751345>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)